Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

15.25USD
26 May 2017
Change (% chg)

$-0.60 (-3.79%)
Prev Close
$15.85
Open
$15.75
Day's High
$15.88
Day's Low
$15.00
Volume
485,050
Avg. Vol
424,231
52-wk High
$35.24
52-wk Low
$7.80

IPXL.OQ

Chart for IPXL.OQ

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $1,123.94
Shares Outstanding(Mil.): 73.70
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): -- 14.27 17.41
EPS (TTM): -7.84 -- --
ROI: -38.12 -7.17 -5.42
ROE: -69.56 -6.63 -4.68

BRIEF-Impax to review strategic alternatives for Taiwan manufacturing site

* Q1 revenue $184.4 million versus i/b/e/s view $191.2 million

May 10 2017

Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.

Apr 26 2017

UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

April 26 Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.

Apr 26 2017

BRIEF-Impax announces FDA approval and launch of a generic version of vytorin

* Impax announces FDA approval and launch of a generic version of vytorin (ezetimibe/simvastatin tablets)

Apr 26 2017

FDA approves Impax generic of Merck's cholesterol drug Vytorin

April 26 The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug Vytorin, the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales.

Apr 26 2017

BRIEF-Impax announces favorable ruling regarding patent validity for Zomig Nasal Spray

* Impax announces favorable ruling regarding patent validity for Zomig (zolmitriptan) Nasal Spray

Mar 30 2017

Impax Labs names industry veteran Paul Bisaro as CEO, shares soar

Impax Laboratories Inc, which is said to be conducting a strategic review, named former Allergan Plc executive and industry veteran Paul Bisaro as its chief executive, sending the drugmaker's shares soaring as much as 38 percent.

Mar 27 2017

Impax Labs names industry veteran Paul Bisaro as CEO, shares soar

March 27 Impax Laboratories Inc, which is said to be conducting a strategic review, named former Allergan Plc executive and industry veteran Paul Bisaro as its chief executive, sending the drugmaker's shares soaring as much as 38 percent.

Mar 27 2017

BRIEF-Impax board of directors appoints Paul M. Bisaro president and CEO

* Impax board of directors appoints Paul M. Bisaro president and CEO

Mar 27 2017

Exclusive: Impax Laboratories taps Morgan Stanley for strategic review - sources

Generic drugmaker Impax Laboratories Inc has asked investment bank Morgan Stanley to help it conduct a strategic review, as it tries to cope with a tougher drug pricing environment, people familiar with the matter said.

Mar 07 2017

More From Around the Web

Earnings vs. Estimates